Anti-tumor necrosis factor therapy was not associated with greater risk for mortality than standard therapy in rheumatoid arthritis
- Review: Anti-tumor necrosis factor antibody therapy for rheumatoid arthritis increases risk for serious infection and malignancy. // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p65
The article presents information on a medical study related to the anti-tumor necrosis factor (anti-TNF) antibody therapy for rheumatoid arthritis. When the study was carried out in patients with rheumatoid arthritis, TNF antibody therapy increased risk for both serious infection and malignancy...
- Patients with rheumatoid arthritis may be at risk for nonmelanoma skin cancers. // Hem/Onc Today;12/10/2012, Vol. 13 Issue 23, p31
The article discusses research which examined the risk for nonmelanoma skin cancers in patients with rheumatoid arthritis who received anti-tumor necrosis factor therapy.
- 2010 - Anti-tumor necrosis factor therapy was not associated with greater risk for mortality than standard therapy in rheumatoid arthritis. Schattner, Ami // ACP Journal Club;3/20/2011, Vol. 154 Issue 3, p12
Question In patients with rheumatoid arthritis (RA), is anti-tumor necrosis factor (anti-TNF) therapy associated with different risk for mortality than disease-modifying antirheumatic drugs (DMARDs)? Methods Design Cohort study with mean follow-up of 4 years in the anti-TNF cohort and 2.7 years...
- Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? // International Journal of Advances in Rheumatology;2010, Vol. 8 Issue 1, p37
The article reports on the findings of the study which examined the risk of cancers in rheumatoid arthritis (RA) patients treated with anti-tumor necrosis factor (anti-TNF) alpha therapies in Sweden.
- Anti-TNF antibodies linked to malignancy/serious infection. // Reactions Weekly;6/3/2006, Issue 1104, p4
Discusses a research on the association of anti-tumor necrosis factor antibody therapy in rheumatoid arthritis with an increased risk of malignancies and serious infections. Reference to a study by T. Bongartz et al, published in the May 17, 2006 issue of the "Journal of the American Medical...
- Patients treated with anti-TNF at increased risk of malignancies. // Nursing Standard;7/12/2006, Vol. 20 Issue 44, p18
The article refers to the anti-Tumor necrosis factor (TNF) therapy. It has been found that patients with rheumatoid arthritis treated with anti-TNF therapy are open to an increased risk of serious infection and malignancies. A significant role is played by Tumor necrosis factor in host defence...
- Infections in biological agents used in rheumatic disease. Byng-Maddick, Rachel; Ehrenstein, Michael // British Journal of Hospital Medicine (17508460);Sep2012, Vol. 73 Issue 9, p517
The article discusses the risk of infection associated with the several targeted biological therapies used to treat rheumatoid arthritis (RA). The 5 anti-tumor necrosis factor a (TNF-a) therapies that are currently available are associated with increased risk for tuberculosis and reactivation of...
- Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factor-Î± therapy. Salvatierra, Juan; Magro-Checa, Cesar; Rosales-Alexander, Jose L.; Raya-Alvarez, Enrique // Rheumatology;Jul2011, Vol. 50 Issue 7, p1346
A letter to the editor is presented in response to "Acute Sarcoidosis As Parotid Fever in Rheumatoid Arthritis Under Anti-Tumor Necrosis Factor-Î± Therapy," previously published in "Rheumatology."
- Anti-TNF alpha therapy, lipid profile and carotid intimal thickness. ARMSTRONG, D. J. // Rheumatology;Oct2007, Vol. 46 Issue 10, p1626
A letter to the editor is presented in response to an article by F. Del Porto et al reporting significant reduction in carotid intimal thickness in patients with rheumatoid arthritis suitable for anti-tumor necrosis factor therapy.